Kintara Therapeutics is a brand dedicated to developing groundbreaking solid tumor cancer therapies for patients with unmet medical needs. With a strong focus on patient wellbeing, their mission is to improve patient outcomes and enhance their quality of life. The brand upholds the highest standards of professionalism, ethics, and transparency in all their actions and communications with stakeholders.

Kintara Therapeutics collaborates with renowned academic and clinical research institutions worldwide to support the development of their novel cancer therapies. They have a strong pipeline of breakthrough therapeutics, including VAL-083, a first-in-class DNA-targeting agent that has shown promise against a range of tumor types such as glioblastoma, pediatric CNS tumors, and ovarian cancer. Additionally, they have REM-001, a second-generation photosensitizer drug with indications for cutaneous metastatic breast cancer, recurrent basal cell carcinoma, nevus syndrome, and hemodialysis arteriovenous (AV) access.

With a platform strategy rooted in a deep understanding of cancer biology, Kintara Therapeutics aims to solve problems in the treatment of drug and immune-resistant cancer. They partner with respected research centers globally and have a strong leadership team with expertise in drug discovery, development, and translational cancer biology. Join the team at Kintara Therapeutics and be a part of their mission to make a difference in the lives of cancer patients.

To learn more about their innovative cancer therapies, get in touch with them today